echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > The first KRAS anti-cancer therapy was born. In the past 40 years, how have scientists overcome the indispensability?

    The first KRAS anti-cancer therapy was born. In the past 40 years, how have scientists overcome the indispensability?

    • Last Update: 2021-08-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ▎The editors of WuXi AppTec's content team have been sharpening their swords for 40 years.
    What breakthroughs lie behind conquering the famous "unable to drug" targets? In May 2021, the KRAS inhibitor sotorasib developed by Amgen was approved by the US FDA, becoming the world's first anti-cancer therapy targeting specific KRAS gene mutations
    .

    KRAS gene mutation is one of the most common carcinogenic mutations in cancer patients, and it is also a well-known "non-drugable" target
    .

    This approval means that mankind has overcome the undrugability of the KRAS target
    .

    In the past 40 years, how did scientists break through the "undrugability" of KRAS and achieve a scientific victory? Read the original article Dr.
    Wang Yinxiang, CEO of Jacos Pharmaceuticals: Where will the development of KRAS targeted anti-cancer drugs go? In China, the development of new drugs for the KRAS target is in progress: BeiGene has reached a cooperation with Amgen on the development of sotorasib in China; Zai Lab has also introduced the rights and interests of an under-developed KRAS inhibitor in Greater China; The KRAS pipelines of many companies, including Jacos Pharmaceuticals, have successively entered clinical development
    .

    Dr.
    Wang Yinxiang, CEO of Jacos Pharmaceuticals, recently discussed the two major challenges facing the development of KRAS targeted therapy and the four major development trends in the future
    .

    Read more about the milestone in the development of KRAS targeted therapy: the world ushered in the first KRAS inhibitor, benefiting patients with non-small cell lung cancer (Source: WuXi AppTec) Frontier: One of the most common cancer mutation genes in humans has emerged Frontier of drug resistance mutations (Source: Academic Jingwei): For the two most common carcinogenic mutations, the latest research has found a new treatment strategy for the "King of Cancer" (Source: Academic Jingwei) Pipeline: KRAS inhibitors are recognized by the FDA as a breakthrough therapy.
    Ding has development rights in the Greater China region (Source: WuXi AppTec) Pipeline: Gakus Pharmaceuticals KRAS inhibitors are approved for clinical use in China (Source: Pharmaceutical Guanlan) Pipeline: Qin Hao Pharmaceuticals KRAS inhibitors are approved for clinical use in China (Sources : Pharmaceutical Guanlan) Follow WuXi AppTec's WeChat matrix for more information
    .

    Swipe left and right on WuXi AppTec's WeChat WeChat matrix to view more, long press to scan the QR code to follow WuXi AppTec's content team and prepare more in-depth analysis reports, scientific research activities, patent layout, investment and financing status, R&D database and other in-depth information for you
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.